Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
04 January 2022 - 11:58PM
Business Wire
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage
biotechnology company pioneering a new approach to treat complex
diseases using multi-targeted endogenous metabolic modulator (EMM)
compositions, today announced that President and Chief Executive
Officer Bill Hinshaw will be presenting at the H.C. Wainwright
BioConnect Conference.
A webcast of this presentation will be available on the
“Investors & News” section of the company’s website,
www.axcellatx.com, at 7:00 a.m. ET on January 10, 2022. A replay
will be accessible on Axcella’s website for 90 days following the
event.
Internet Posting of Information Axcella uses its website,
www.axcellahealth.com, as a means of disclosing material nonpublic
information and for complying with its disclosure obligations under
Regulation FD. Such disclosures will be included on the company’s
website in the “Investors & News” section. Accordingly,
investors should monitor this portion of the company’s website, in
addition to its press releases, SEC filings and public conference
calls and webcasts.
About Axcella Therapeutics (Nasdaq: AXLA) Axcella is a
clinical-stage biotechnology company pioneering a new approach to
treat complex diseases using endogenous metabolic modulator (EMM)
compositions. The company’s product candidates are comprised of
EMMs and derivatives that are engineered in distinct combinations
and ratios to restore cellular homeostasis in multiple key
biological pathways and improve cellular energetic efficiency.
Axcella’s pipeline includes lead therapeutic candidates in Phase 2
development for the reduction in risk of overt hepatic
encephalopathy (OHE) recurrence, the treatment of Long COVID, and
the treatment of non-alcoholic steatohepatitis (NASH). The
company’s unique model allows for the evaluation of its EMM
compositions through non-IND clinical studies or IND clinical
trials. For more information, please visit www.axcellatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220103005465/en/
Jason Fredette jfredette@axcellatx.com (857) 320-2236
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2023 to Mar 2024